Researchers at UW–Madison have provided new insights into an alternative vaccine approach that provides broader protection against seasonal influenza as well as other respiratory pathogens, including COVID-19. The experimental vaccine delivered long-lasting, multi-pronged protection in the lungs of mice by rallying T-cells, specialist white blood cells that quickly eliminate viral invaders through an immune response. The research suggests a potential strategy for developing a universal flu vaccine so a new vaccine does not have to be developed every year.
NIH
The National Institutes of Health (NIH) is the world’s premier biomedical research funding agency, competitively awarding grants to scientists at universities in all 50 states.
At UW–Madison, the awards we receive from NIH support a broad array of human health research, from heart disease to fertility to asthma.